Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR versus octreotide LAR in active acromegaly
2007-001972-36Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2007
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acromegaly comparing Pasireotide LAR with Octreotide LAR (2 arms). Primary endpoint: Biochemical control at 12 months. Started Sep 2007; status: completed.
02
Drugs
pasireotide LARoctreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2007-001972-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001972-36.